Publications Search

Search for publications by author
Search for publications by abstract keyword(s)

Worsening of soft tissue dystrophic calcification in an osteoporotic patient treated with teriparatide


Teriparatide, used for treatment of osteoporosis in patients at high risk of fracture risk, sometimes results in mild and transient hypercalcemia. There have been two recent reports of worsening dystrophic calcification in patients with autoimmune disorders following teriparatide treatment. We report a patient with severe osteoporosis and without a pre-existing autoimmune disorder, who developed symptomatic worsening of dystrophic calcification 4 months after teriparatide was initiated. Symptoms resolved within 1 week of teriparatide cessation.

Type Journal
ISBN 1433-2965 (Electronic) 0937-941X (Linking)
Authors Htet, T. D.; Eisman, J. A.; Elder, G. J.; Center, J. R.
Responsible Garvan Author Prof Jacqueline Center
Published Date 2018-02-01
Published Volume 29
Published Issue 2
Published Pages 517-518
Status Published in-print
DOI 10.1007/s00198-017-4330-7
URL link to publisher's version